Recent Patents Concerning Modulators of Protein Kinase C
Sonia Sanchez-Bautista and Francisco E. Nicolas
Affiliation: Department of Nursing, Catholic University of Murcia (UCAM), 30107, Murcia, Spain.
Keywords: Protein kinase C, inhibitors, activators, modulators, antisense oligonucleotide, biomarkers, PKC isoforms, atherosclerosis, pseudosubstrate, Novel isozymes, catalytic domain, inflammatory diseases, sotrastaurin, maleimide compound, Inhibitors in Cancer, Metastases, myocardial infarction
Protein kinase C (PKC) comprises a family of 10 serine/threonine kinases divided into 3 subfamilies: classical,
novel and atypical. These isoenzymes represent one of the major mediators of signal transduction, and most may be
associated with several pathogenic processes including malignant transformation or cancer and metastasis. Moreover, some
activated isoenzymes are also involved in other diseases such as infarct, rejection due to incomplete histocompatibility in
organ transplantation, pain, diabetic macular edema, etc. Here, we review several patents related to inhibitors of PKC that
represent a new and promising strategy for the prevention and treatment of these illnesses. Among these inhibitors, we
included antisense oligonucleotides as another useful strategy to treat infectious and autoimmune diseases associated with
misregulated expression of PKC and tumour necrosis factor alpha (TNF-α). On the other hand, two different activators of
PKC and their applications related to neurodegenerative diseases have also been reviewed in this work.
Rights & PermissionsPrintExport